Bristol Myers Squibb Company has been in Cobenfy (xanomeline and trospium chloride) launch mode for several months in anticipation of the US Food and Drug Administration’s approval decision of the M1/M4 muscarinic agonist as a treatment for adults with schizophrenia, which the agency granted as scheduled on 26 September. BMS plans to make the drug – formerly known as KarXT, which it acquired in the $14bn purchase of Karuna Therapeutics, Inc. – available within the next month.
Key Takeaways
-
BMS won US FDA approval for Cobenfy, previously known as KarXT, for adults with schizophrenia. The drug was developed by Karuna Therapeutics, which the company bought for $14bn.
-
Cobenfy offers the first new antipsychotic mechanism of action in decades with strong efficacy across several clinical trials and better safety and tolerability than atypical antipsychotics
Chief commercialization officer Adam Lenkowsky told Scrip that Cobenfy’s wholesale acquisition cost (WAC) of $1,850 for a 30-day supply, or $22,500 annually, is in line with other approved brand-name antipsychotic medicines, while reflecting the product’s novel mechanism of action – the first new MOA in schizophrenia in decades – that confers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?